Bridging the Gap: Immunotherapy in Progressive Multifocal Leukoencephalopathy: A New Hope?
- PMID: 37407265
- PMCID: PMC10558171
- DOI: 10.1212/WNL.0000000000207533
Bridging the Gap: Immunotherapy in Progressive Multifocal Leukoencephalopathy: A New Hope?
Abstract
Progressive multifocal leukoencephalopathy (PML) is a severe infection of the CNS occurring in immunocompromised individuals in which large demyelinating lesions are induced by polyomavirus JC (JCV). In the absence of effective antiviral treatment, control of the infection relies on restoring anti-JCV immunity. Thus, particularly in long-standing immunocompromising conditions such as organ transplantation, lymphoproliferative disorders, or idiopathic lymphopenia, new strategies to boost anti-JCV immune responses are needed. Here, we report the case of a patient developing PML in the context of kidney transplantation who received recombinant human interleukin 7 to foster immune responses against JCV. We give an overview of the immunologic mechanisms underlying the development of PML and immune restoration within the CNS after JCV infection. Immunotherapeutic strategies developed based on current understanding of the disease hold promise in managing patients with PML.
© 2023 American Academy of Neurology.
Conflict of interest statement
The authors report no relevant disclosures. Go to
Figures
References
-
- Martin-Blondel G, Bauer J, Uro-Coste E, et al. . Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8+ T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome. Acta Neuropathol. 2015;129(3):463-465. doi:10.1007/s00401-015-1383-6 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous